JPWO2022216831A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022216831A5 JPWO2022216831A5 JP2023562566A JP2023562566A JPWO2022216831A5 JP WO2022216831 A5 JPWO2022216831 A5 JP WO2022216831A5 JP 2023562566 A JP2023562566 A JP 2023562566A JP 2023562566 A JP2023562566 A JP 2023562566A JP WO2022216831 A5 JPWO2022216831 A5 JP WO2022216831A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- natural killer
- pharmaceutical combination
- population
- killer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172414P | 2021-04-08 | 2021-04-08 | |
| US63/172,414 | 2021-04-08 | ||
| US202163290359P | 2021-12-16 | 2021-12-16 | |
| US63/290,359 | 2021-12-16 | ||
| PCT/US2022/023684 WO2022216831A1 (en) | 2021-04-08 | 2022-04-06 | Treatment of cancer with nk cells and a her2 targeted antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513522A JP2024513522A (ja) | 2024-03-25 |
| JP2024513522A5 JP2024513522A5 (https=) | 2025-04-14 |
| JPWO2022216831A5 true JPWO2022216831A5 (https=) | 2025-04-14 |
Family
ID=83545892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562566A Pending JP2024513522A (ja) | 2021-04-08 | 2022-04-06 | Ｎｋ細胞およびｈｅｒ２標的抗体を用いた癌治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240197778A1 (https=) |
| EP (1) | EP4319771A4 (https=) |
| JP (1) | JP2024513522A (https=) |
| KR (1) | KR20240024048A (https=) |
| AU (1) | AU2022254689A1 (https=) |
| WO (1) | WO2022216831A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| EP3633029A4 (en) | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| US12116417B2 (en) | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| MY199770A (en) | 2018-11-14 | 2023-11-22 | Green Cross Lab Cell Corp | Method for culturing cord blood-derived natural killer cells using transformed t cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7171433B2 (ja) * | 2015-10-30 | 2022-11-15 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法 |
| CN107267454B (zh) * | 2016-04-07 | 2025-05-23 | 内蒙古原生元生物科技有限公司 | 一种脐血nk细胞的体外扩增方法及其试剂盒与应用 |
| AU2017268839A1 (en) * | 2016-05-27 | 2018-11-29 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders |
| WO2018124766A2 (ko) * | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| EP4474391A3 (en) * | 2018-05-14 | 2025-02-26 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
-
2022
- 2022-04-06 AU AU2022254689A patent/AU2022254689A1/en not_active Abandoned
- 2022-04-06 US US18/285,647 patent/US20240197778A1/en active Pending
- 2022-04-06 KR KR1020237038625A patent/KR20240024048A/ko not_active Withdrawn
- 2022-04-06 WO PCT/US2022/023684 patent/WO2022216831A1/en not_active Ceased
- 2022-04-06 EP EP22785376.9A patent/EP4319771A4/en active Pending
- 2022-04-06 JP JP2023562566A patent/JP2024513522A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cohen et al. | CD4+ CD25+ immunoregulatory T cells: new therapeutics for graft-versus-host disease | |
| Shimasaki et al. | Expanded and armed natural killer cells for cancer treatment | |
| Bordignon et al. | Cell therapy: achievements and perspectives | |
| Bacigalupo | Management of acute graft‐versus‐host disease | |
| Wrzesinski et al. | Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy | |
| Tomuleasa et al. | Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia | |
| Locatelli et al. | At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies | |
| ES2224122T3 (es) | Inmunoterapia de cancer con linfocitos alogenicos. | |
| van Ostaijen-ten Dam et al. | Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential | |
| Tsang et al. | Indefinite mouse heart allograft survival in recipient treated with CD4+ CD25+ regulatory T cells with indirect allospecificity and short term immunosuppression | |
| KR20140092298A (ko) | 항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도 | |
| JP2007527245A (ja) | レギュラトリーｔ細胞並びに免疫療法及び自己免疫応答の抑制におけるそれらの使用 | |
| HK1046928B (en) | Veto cells effective in preventing graft rejection and devoid of graft versus host potential | |
| JP2013014587A (ja) | Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法 | |
| JP2022522231A (ja) | 抗ｂｃｍａ ｃａｒ ｔ細胞の製造 | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| US20250242021A1 (en) | Allogeneic t cells for treatment of hematological malignancies | |
| EP1648508A1 (en) | Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells | |
| Maeda | Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide | |
| JPWO2022216837A5 (https=) | ||
| Li et al. | Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells | |
| Caruso et al. | NK cells as adoptive cellular therapy for hematological malignancies: advantages and hurdles | |
| JPWO2023278811A5 (https=) | ||
| JPWO2022216831A5 (https=) | ||
| Su et al. | Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells |